- Home
- AUDC vs KYTX Comparison
AUDC vs KYTX Comparison
Compare AUDC & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- KYTX
- Stock Information
- Founded
- AUDC 1992
- KYTX 2018
- Country
- AUDC Israel
- KYTX United States
- Employees
- AUDC N/A
- KYTX N/A
- Industry
- AUDC Telecommunications Equipment
- KYTX
- Sector
- AUDC Utilities
- KYTX
- Exchange
- AUDC Nasdaq
- KYTX NYSE
- Market Cap
- AUDC 266.8M
- KYTX 242.1M
- IPO Year
- AUDC 1999
- KYTX 2024
- Fundamental
- Price
- AUDC $8.21
- KYTX $4.35
- Analyst Decision
- AUDC Buy
- KYTX Buy
- Analyst Count
- AUDC 2
- KYTX 5
- Target Price
- AUDC $10.00
- KYTX $23.40
- AVG Volume (30 Days)
- AUDC 99.9K
- KYTX 237.0K
- Earning Date
- AUDC 11-06-2024
- KYTX 11-13-2024
- Dividend Yield
- AUDC 4.38%
- KYTX N/A
- EPS Growth
- AUDC 0.25
- KYTX N/A
- EPS
- AUDC 0.40
- KYTX N/A
- Revenue
- AUDC $244,181,000.00
- KYTX N/A
- Revenue This Year
- AUDC N/A
- KYTX N/A
- Revenue Next Year
- AUDC $21.93
- KYTX N/A
- P/E Ratio
- AUDC $20.45
- KYTX N/A
- Revenue Growth
- AUDC N/A
- KYTX N/A
- 52 Week Low
- AUDC $7.70
- KYTX $4.32
- 52 Week High
- AUDC $14.45
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- AUDC 36.56
- KYTX 33.83
- Support Level
- AUDC $7.70
- KYTX $5.01
- Resistance Level
- AUDC $8.59
- KYTX $5.62
- Average True Range (ATR)
- AUDC 0.34
- KYTX 0.39
- MACD
- AUDC -0.05
- KYTX -0.03
- Stochastic Oscillator
- AUDC 23.72
- KYTX 2.19
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.